Strategic Tissue Repository Alliance through Unified Methods - Revision history

David: David moved page STRATUM to Strategic Tissue Repository Alliance through Unified Methods

2012-11-30T17:34:45Z

David moved page STRATUM to Strategic Tissue Repository Alliance through Unified Methods

David at 17:34, 30 November 2012

2012-11-30T17:34:21Z

Claire Robinson at 15:31, 30 November 2012

2012-11-30T15:31:55Z

Claire Robinson at 14:51, 30 November 2012

2012-11-30T14:51:20Z

Claire Robinson at 14:50, 30 November 2012

2012-11-30T14:50:52Z

Claire Robinson at 14:46, 30 November 2012

2012-11-30T14:46:50Z

Claire Robinson at 14:27, 30 November 2012

2012-11-30T14:27:52Z

Claire Robinson at 14:19, 30 November 2012

2012-11-30T14:19:48Z

Claire Robinson at 14:19, 30 November 2012

2012-11-30T14:19:25Z

Claire Robinson at 14:18, 30 November 2012

2012-11-30T14:18:09Z

← Older revision		Revision as of 17:34, 30 November 2012
Line 1:		Line 1:
−	[[STRATUM]] (Strategic Tissue ~~Repositaory~~ Alliance through Unified Methods) is a biobanking (storage of human tissue samples for research) project, described as "a collaboration between the pharmaceutical industry and academia, led by [[AstraZeneca]]". Other partners of the consortium include [[GlaxoSmithKline]], Lab21 and the universities of Manchester, Nottingham and Leicester.<ref>Genetic Alliance UK (2012) [http://www.geneticalliance.org.uk/projects/stratum.htm Project: Understanding public engagement with biobanking], acc 30 Nov 2012</ref>	+	[[STRATUM]] (Strategic Tissue Repository Alliance through Unified Methods) is a biobanking (storage of human tissue samples for research) project, described as "a collaboration between the pharmaceutical industry and academia, led by [[AstraZeneca]]". Other partners of the consortium include [[GlaxoSmithKline]], Lab21 and the universities of Manchester, Nottingham and Leicester.<ref>Genetic Alliance UK (2012) [http://www.geneticalliance.org.uk/projects/stratum.htm Project: Understanding public engagement with biobanking], acc 30 Nov 2012</ref>

	"Public engagement" for the project is managed by [[Genetic Alliance UK]].<ref>Genetic Alliance UK (2012) [http://www.geneticalliance.org.uk/projects/stratum.htm Project: Understanding public engagement with biobanking], acc 30 Nov 2012</ref>		"Public engagement" for the project is managed by [[Genetic Alliance UK]].<ref>Genetic Alliance UK (2012) [http://www.geneticalliance.org.uk/projects/stratum.htm Project: Understanding public engagement with biobanking], acc 30 Nov 2012</ref>

@@ Line 3: / Line 3: @@
 "Public engagement" for the project is managed by [[Genetic Alliance UK]].<ref>Genetic Alliance UK (2012) [http://www.geneticalliance.org.uk/projects/stratum.htm Project: Understanding public engagement with biobanking], acc 30 Nov 2012</ref>
-STRATUM is one of seven projects under the umbrella of the [[Stratified Medicine Innovation Platform]] (SMIP), a "personalised medicine" initiative led by the [[Technology Strategy Board]], which in turn is an executive non-departmental public body established by the UK Government in 2007 and sponsored by the [[Department for Business, Innovation and Skills]] (BIS). The seven projects are led by [[AstraZeneca]] UK Ltd, [[GlaxoSmithKline]], [[Ig Innovations]] Ltd, [[Janssen Pharmaceutica|Janssen]] UK and [[Randox Laboratories]] Ltd. The Technology Strategy Board and the [[Medical Research Council]] invested over GBP 3.7 million of public money in the seven projects.<ref>Technology Strategy Board (2011) [http://bit.ly/VaygFa Research and development into personalised medicine to receive new government investment], press release, 19 May, acc 30 Nov 2012</ref>
+STRATUM is one of seven projects under the umbrella of the [[Stratified Medicine Innovation Platform]] (SMIP), a "personalised medicine" initiative led by the [[Technology Strategy Board]], which in turn is an executive non-departmental public body established by the UK Government in 2007 and sponsored by the [[Department for Business, Innovation and Skills]] (BIS). The seven projects are led by [[AstraZeneca]] UK Ltd, [[GlaxoSmithKline]], [[Ig Innovations]] Ltd, [[Janssen]] UK and [[Randox Laboratories]] Ltd. The Technology Strategy Board and the [[Medical Research Council]] invested over GBP 3.7 million of public money in the seven projects.<ref>Technology Strategy Board (2011) [http://bit.ly/VaygFa Research and development into personalised medicine to receive new government investment], press release, 19 May, acc 30 Nov 2012</ref>
 ==Notes==
 <references/>
 [[Category:GM]][[Category:Human Genetics]]

@@ Line 3: / Line 3: @@
 "Public engagement" for the project is managed by [[Genetic Alliance UK]].<ref>Genetic Alliance UK (2012) [http://www.geneticalliance.org.uk/projects/stratum.htm Project: Understanding public engagement with biobanking], acc 30 Nov 2012</ref>
-STRATUM is one of seven projects under the umbrella of the [[Stratified Medicine Innovation Platform]] (SMIP), a "personalised medicine" initiative led by the [[Technology Strategy Board]], which in turn is an executive non-departmental public body established by the UK Government in 2007 and sponsored by the [[Department for Business, Innovation and Skills]] (BIS). The seven projects are led by [[AstraZeneca]] UK Ltd, [[GlaxoSmithKline]], [[Ig Innovations]] Ltd, [[Janssen|Janssen Pharmaceutica]] UK and [[Randox Laboratories]] Ltd. The Technology Strategy Board and the [[Medical Research Council]] invested over GBP 3.7 million of public money in the seven projects.<ref>Technology Strategy Board (2011) [http://bit.ly/VaygFa Research and development into personalised medicine to receive new government investment], press release, 19 May, acc 30 Nov 2012</ref>
+STRATUM is one of seven projects under the umbrella of the [[Stratified Medicine Innovation Platform]] (SMIP), a "personalised medicine" initiative led by the [[Technology Strategy Board]], which in turn is an executive non-departmental public body established by the UK Government in 2007 and sponsored by the [[Department for Business, Innovation and Skills]] (BIS). The seven projects are led by [[AstraZeneca]] UK Ltd, [[GlaxoSmithKline]], [[Ig Innovations]] Ltd, [[Janssen Pharmaceutica|Janssen]] UK and [[Randox Laboratories]] Ltd. The Technology Strategy Board and the [[Medical Research Council]] invested over GBP 3.7 million of public money in the seven projects.<ref>Technology Strategy Board (2011) [http://bit.ly/VaygFa Research and development into personalised medicine to receive new government investment], press release, 19 May, acc 30 Nov 2012</ref>
 ==Notes==
 <references/>
 [[Category:GM]][[Category:Human Genetics]]

@@ Line 3: / Line 3: @@
 "Public engagement" for the project is managed by [[Genetic Alliance UK]].<ref>Genetic Alliance UK (2012) [http://www.geneticalliance.org.uk/projects/stratum.htm Project: Understanding public engagement with biobanking], acc 30 Nov 2012</ref>
-STRATUM is one of seven projects under the umbrella of the [[Stratified Medicine Innovation Platform]] (SMIP), a "personalised medicine" initiative led by the [[Technology Strategy Board]], which in turn is an executive non-departmental public body established by the UK Government in 2007 and sponsored by the [[Department for Business, Innovation and Skills]] (BIS). The seven projects are led by [[AstraZeneca]] UK Ltd, [[GlaxoSmithKline]], [[Ig Innovations]] Ltd, [[Janssen]] UK and [[Randox Laboratories]] Ltd. The Technology Strategy Board and the [[Medical Research Council]] invested over GBP 3.7 million of public money in the seven projects.<ref>Technology Strategy Board (2011) [http://bit.ly/VaygFa Research and development into personalised medicine to receive new government investment], press release, 19 May, acc 30 Nov 2012</ref>
+STRATUM is one of seven projects under the umbrella of the [[Stratified Medicine Innovation Platform]] (SMIP), a "personalised medicine" initiative led by the [[Technology Strategy Board]], which in turn is an executive non-departmental public body established by the UK Government in 2007 and sponsored by the [[Department for Business, Innovation and Skills]] (BIS). The seven projects are led by [[AstraZeneca]] UK Ltd, [[GlaxoSmithKline]], [[Ig Innovations]] Ltd, [[Janssen|Janssen Pharmaceutica]] UK and [[Randox Laboratories]] Ltd. The Technology Strategy Board and the [[Medical Research Council]] invested over GBP 3.7 million of public money in the seven projects.<ref>Technology Strategy Board (2011) [http://bit.ly/VaygFa Research and development into personalised medicine to receive new government investment], press release, 19 May, acc 30 Nov 2012</ref>
 ==Notes==
 <references/>
 [[Category:GM]][[Category:Human Genetics]]

@@ Line 2: / Line 2: @@
 "Public engagement" for the project is managed by [[Genetic Alliance UK]].<ref>Genetic Alliance UK (2012) [http://www.geneticalliance.org.uk/projects/stratum.htm Project: Understanding public engagement with biobanking], acc 30 Nov 2012</ref>
 ==Notes==
 <references/>
 [[Category:GM]][[Category:Human Genetics]]

← Older revision	Revision as of 17:34, 30 November 2012
(No difference)

← Older revision		Revision as of 14:27, 30 November 2012
Line 1:		Line 1:
−	[[STRATUM]] is a biobanking (storage of human tissue samples for research) project, described as "a collaboration between the pharmaceutical industry and academia, led by [[AstraZeneca]]". Other partners of the consortium include [[GlaxoSmithKline]], Lab21 and the universities of Manchester, Nottingham and Leicester.<ref>Genetic Alliance UK (2012) [http://www.geneticalliance.org.uk/projects/stratum.htm Project: Understanding public engagement with biobanking], acc 30 Nov 2012</ref>	+	[[STRATUM]] (Strategic Tissue Repositaory Alliance through Unified Methods) is a biobanking (storage of human tissue samples for research) project, described as "a collaboration between the pharmaceutical industry and academia, led by [[AstraZeneca]]". Other partners of the consortium include [[GlaxoSmithKline]], Lab21 and the universities of Manchester, Nottingham and Leicester.<ref>Genetic Alliance UK (2012) [http://www.geneticalliance.org.uk/projects/stratum.htm Project: Understanding public engagement with biobanking], acc 30 Nov 2012</ref>

	"Public engagement" for the project is managed by [[Genetic Alliance UK]].<ref>Genetic Alliance UK (2012) [http://www.geneticalliance.org.uk/projects/stratum.htm Project: Understanding public engagement with biobanking], acc 30 Nov 2012</ref>		"Public engagement" for the project is managed by [[Genetic Alliance UK]].<ref>Genetic Alliance UK (2012) [http://www.geneticalliance.org.uk/projects/stratum.htm Project: Understanding public engagement with biobanking], acc 30 Nov 2012</ref>

← Older revision		Revision as of 14:19, 30 November 2012
Line 1:		Line 1:
−	[[STRATUM]] is a biobanking (storage of human tissue samples for research) project, ~~formed~~ as ~~a result of~~ "a collaboration between the pharmaceutical industry and academia, led by [[AstraZeneca]]". Other partners of the consortium include [[GlaxoSmithKline]], Lab21 and the universities of Manchester, Nottingham and Leicester.<ref>Genetic Alliance UK (2012) [http://www.geneticalliance.org.uk/projects/stratum.htm Project: Understanding public engagement with biobanking], acc 30 Nov 2012</ref>	+	[[STRATUM]] is a biobanking (storage of human tissue samples for research) project, described as "a collaboration between the pharmaceutical industry and academia, led by [[AstraZeneca]]". Other partners of the consortium include [[GlaxoSmithKline]], Lab21 and the universities of Manchester, Nottingham and Leicester.<ref>Genetic Alliance UK (2012) [http://www.geneticalliance.org.uk/projects/stratum.htm Project: Understanding public engagement with biobanking], acc 30 Nov 2012</ref>

	"Public engagement" for the project is managed by [[Genetic Alliance UK]].<ref>Genetic Alliance UK (2012) [http://www.geneticalliance.org.uk/projects/stratum.htm Project: Understanding public engagement with biobanking], acc 30 Nov 2012</ref>		"Public engagement" for the project is managed by [[Genetic Alliance UK]].<ref>Genetic Alliance UK (2012) [http://www.geneticalliance.org.uk/projects/stratum.htm Project: Understanding public engagement with biobanking], acc 30 Nov 2012</ref>